Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Open Access
- 22 November 1999
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 159 (21) , 2542-2550
- https://doi.org/10.1001/archinte.159.21.2542
Abstract
CURRENT treatments for rheumatoid arthritis (RA) include nonsteroidal anti-inflammatory drugs (NSAIDs), low-dose steroids, and disease-modifying antirheumatic drugs (DMARDs). The active control drug for this study, methotrexate, is considered to be the "gold standard" DMARD for the treatment of RA.1-4 No currently available medication is uniformly effective, however, and all may cause significant adverse effects.5Keywords
This publication has 8 references indexed in Scilit:
- Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritisArthritis & Rheumatism, 1999
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinNew England Journal of Medicine, 1997
- The Immunosuppressive Metabolite of Leflunomide Is a Potent Inhibitor of Human Dihydroorotate DehydrogenaseBiochemistry, 1996
- Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritisArthritis & Rheumatism, 1995
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Weekly Pulse Methotrexate in Rheumatoid ArthritisAnnals of Internal Medicine, 1985
- Efficacy of Low-Dose Methotrexate in Rheumatoid ArthritisNew England Journal of Medicine, 1985
- Assessment of patient satisfaction in activities of daily living using a modified stanford health assessment questionnaireArthritis & Rheumatism, 1983